{
    "organizations": [],
    "uuid": "9438f645827b4cb8e19695b4d5bea176ef25e0ee",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-myriad-receives-pre-market-approva/brief-myriad-receives-pre-market-approval-for-its-bracanalysis-diagnostic-system-in-japan-idUSFWN1RF067",
    "ord_in_thread": 0,
    "title": "BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :\n* MARKET APPROVAL FOR ITS BRACANALYSIS® DIAGNOSTIC SYSTEM IN JAPAN\n* MUTATED METASTATIC BREAST CANCER​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-02T19:39:00.000+03:00",
    "crawled": "2018-04-03T16:05:58.123+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "myriad",
        "genetics",
        "inc",
        "merck",
        "seeking",
        "approval",
        "lynparza",
        "japan",
        "treating",
        "patient",
        "brca",
        "market",
        "approval",
        "diagnostic",
        "system",
        "japan",
        "mutated",
        "metastatic",
        "breast",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}